$
138.900
-2.165(-1.535%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
143.360
Open
142.050
VWAP
140.13
Vol
1.20M
Mkt Cap
18.97B
Low
138.240
Amount
168.60M
EV/EBITDA(TTM)
--
Total Shares
122.80M
EV
18.06B
EV/OCF(TTM)
117.92
P/S(TTM)
9.73
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
519.40M
+9.1%
--
--
500.51M
+13.81%
--
--
476.77M
+15.34%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Natera, Inc. (NTRA) for FY2025, with the revenue forecasts being adjusted by 3.69% over the past three months. During the same period, the stock price has changed by -9.21%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.69%
In Past 3 Month
Stock Price
Go Down
down Image
-9.21%
In Past 3 Month
11 Analyst Rating
up Image
48.60% Upside
Wall Street analysts forecast NTRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 206.40 USD with a low forecast of 185.00 USD and a high forecast of 251.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
up Image
48.60% Upside
Current: 138.900
sliders
Low
185.00
Averages
206.40
High
251.00
Piper Sandler
Overweight
maintain
$205 -> $210
2025-05-15
Reason
Piper Sandler raised the firm's price target on Natera to $210 from $205 following quarterly results. The firm keeps an Overweight rating on the shares.
Barclays
NULL -> Overweight
upgrade
$160 -> $190
2025-05-09
Reason
Barclays raised the firm's price target on Natera to $190 from $160 and keeps an Overweight rating on the shares. The firm updated the company's model post the earnings report.
BTIG
Buy
maintain
$190 -> $195
2025-05-09
Reason
BTIG raised the firm's price target on Natera to $195 from $190 and keeps a Buy rating on the shares. The company delivered a strong Q1 earnings beat and raise, and Q1 was highlighted by record unit growth on a sequential basis in its Signatera MRD business, the analyst tells investors in a research note. Natera's drivers - robust volume growth across products, opportunities for average selling price expansion, new test offerings, and significant upside potential from updated guideline bodies - remain intact, the firm adds.
UBS
Dan Leonard
Buy
maintain
$211 -> $218
2025-05-09
Reason
UBS analyst Dan Leonard raised the firm's price target on Natera to $218 from $211 and keeps a Buy rating on the shares.
TD Cowen
Dan Brennan
Buy
maintain
$195 -> $200
2025-05-09
Reason
Barclays
Luke Sergott
Buy
Maintains
$200 → $160
2025-04-10
Reason
Barclays lowered the firm's price target on Natera to $160 from $200 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.

Valuation Metrics

The current forward P/E ratio for Natera Inc (NTRA.O) is -65.04, compared to its 5-year average forward P/E of -32.31. For a more detailed relative valuation and DCF analysis to assess Natera Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-32.31
Current PE
-65.04
Overvalued PE
-5.01
Undervalued PE
-59.60

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-33.13
Current EV/EBITDA
-67.56
Overvalued EV/EBITDA
-4.57
Undervalued EV/EBITDA
-61.68

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
9.25
Current PS
9.22
Overvalued PS
13.50
Undervalued PS
5.00

Financials

Annual
Quarterly
FY2025Q1
YoY :
+36.46%
501.83M
Total Revenue
FY2025Q1
YoY :
+6.54%
-79.18M
Operating Profit
FY2025Q1
YoY :
-0.98%
-66.94M
Net Income after Tax
FY2025Q1
YoY :
-10.71%
-0.50
EPS - Diluted
FY2025Q1
YoY :
-694.30%
22.64M
Free Cash Flow
FY2025Q1
YoY :
+11.28%
63.12
Gross Profit Margin - %
FY2025Q1
YoY :
-128.46%
4.65
FCF Margin - %
FY2025Q1
YoY :
-27.42%
-13.34
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
22.3M
USD
33
3-6
Months
42.6M
USD
43
6-9
Months
97.0M
USD
40
0-12
Months
10.2M
USD
31
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 265.72% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.4M
Volume
6
6-9
Months
1.6M
Volume
11
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
7
1.0M
Volume
Months
6-9
5
278.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
8.0K
USD
Months
0-12
0
0.0
USD
Months

NTRA News & Events

Events Timeline

2025-07-07 (ET)
2025-07-07
07:19:06
Natera presents data from Latitude MRD assay study at ESMO Congress
select
2025-06-04 (ET)
2025-06-04
07:32:49
Natera announces Medicare coverage for Signatera MRD assay
select
2025-05-08 (ET)
2025-05-08
16:46:44
Natera raises FY25 revenue view to $1.94B-$2.02B, consensus $1.92B
select
Sign Up For More Events

News

5.0
07-23NASDAQ.COM
Insider Sale: SEC. AND CHIEF LEGAL OFFICER of $NTRA Sells 10,000 Shares
2.0
07-20Benzinga
Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?
2.0
07-15NASDAQ.COM
Notable Two Hundred Day Moving Average Cross - NTRA
Sign Up For More News

FAQ

arrow icon

What is Natera Inc (NTRA) stock price today?

The current price of NTRA is 138.9 USD — it has decreased -1.53 % in the last trading day.

arrow icon

What is Natera Inc (NTRA)'s business?

arrow icon

What is the price predicton of NTRA Stock?

arrow icon

What is Natera Inc (NTRA)'s revenue for the last quarter?

arrow icon

What is Natera Inc (NTRA)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Natera Inc (NTRA)'s fundamentals?

arrow icon

How many employees does Natera Inc (NTRA). have?

arrow icon

What is Natera Inc (NTRA) market cap?